Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
暂无分享,去创建一个
Yanfeng Gao | Jiangfeng Du | Wenjie Zhai | Wenshan Zhao | Junhui Chen | Xiuman Zhou | Hongfei Wang | Chunxia Chen | Xiaowen Zhou | Shanshan Gou | Ling Jiao | Shaomeng Chen | Xiangrui Cheng
[1] V. Kuchroo,et al. TIGIT predominantly regulates the immune response via regulatory T cells , 2024, The Journal of clinical investigation.
[2] Yanfeng Gao,et al. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses , 2020, Acta pharmaceutica Sinica. B.
[3] Young Hak Kim,et al. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab , 2019, Scientific Reports.
[4] D. Vignali,et al. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups , 2019, Nature Immunology.
[5] Yuzhen Wang,et al. Anticancer activity of emodin is associated with downregulation of CD155. , 2019, International immunopharmacology.
[6] A. Kulkarni,et al. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma , 2019, Cancer Immunology Research.
[7] I. Benhar,et al. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[8] Xiangguo Duan,et al. Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway , 2019, Journal of cellular and molecular medicine.
[9] O. Ashur-Fabian,et al. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies , 2019, Front. Endocrinol..
[10] Xiaoye Zhang,et al. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors , 2019, Oncology letters.
[11] J. Chisholm,et al. The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves , 2019, The Journal of Immunology.
[12] Yanfeng Gao,et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells , 2018, Front. Immunol..
[13] Lieping Chen,et al. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.
[14] M. Ramachandra,et al. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways , 2018, BioDrugs.
[15] Huan Wang,et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.
[16] Baobiao Zhuo,et al. Overexpression of CD155 relates to metastasis and invasion in osteosarcoma. , 2018, Oncology letters.
[17] Z. Qian,et al. Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy , 2018, Advanced science.
[18] Xinlin Chen,et al. CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. , 2017, Cancer research.
[19] Jun S. Liu,et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.
[20] K. Excoffon,et al. Poliovirus Receptor: More than a simple viral receptor. , 2017, Virus research.
[21] Huanling Zhang,et al. High-affinity human PD-L1 variants attenuate the suppression of T cell activation , 2017, Oncotarget.
[22] J. Kirchmair,et al. Data Resources for the Computer-Guided Discovery of Bioactive Natural Products , 2017, J. Chem. Inf. Model..
[23] Wei Wang,et al. CD155 knockdown promotes apoptosis via AKT/Bcl‐2/Bax in colon cancer cells , 2017, Journal of cellular and molecular medicine.
[24] A. Ribas,et al. Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.
[25] Jianjian Peng,et al. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. , 2016, International immunopharmacology.
[26] Lei Liu,et al. Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. , 2015, Angewandte Chemie.
[27] Axel Hoos,et al. Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.
[28] J. Hackney,et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.
[29] C. Li,et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells , 2012, Cell Death and Differentiation.
[30] Jianping Yin,et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering , 2012, Proceedings of the National Academy of Sciences.
[31] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.
[32] D. Louis,et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration , 2004, BMC Cancer.
[33] L. Moretta,et al. Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.
[34] E. Wimmer,et al. Poliovirus can enter and infect mammalian cells by way of an intercellular adhesion molecule 1 pathway. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[35] E. Wimmer,et al. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily , 1989, Cell.
[36] Yanfeng Gao,et al. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1. , 2019, Methods in enzymology.
[37] E. Chiang,et al. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. , 2017, Trends in immunology.
[38] R. Scolyer,et al. Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.
[39] Y. Kawakami,et al. Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2015, The Journal of investigative dermatology.
[40] H. Clark,et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.
[41] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..